Taurine
Taurine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aminosyn-pf | New Drug Application | 2022-07-21 |
| gze yellow peeling oil | C200263 | 2024-11-10 |
| lingtea | unapproved drug other | 2018-06-24 |
| premasol - sulfite-free (amino acid) | ANDA | 2022-08-04 |
| trophamine | New Drug Application | 2023-11-27 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
164 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 1 | 8 | 3 | 13 | 3 | 27 |
| Fatigue | D005221 | — | R53.83 | — | — | — | 1 | 5 | 6 |
| Depression | D003863 | — | F33.9 | 1 | 2 | 1 | 1 | 1 | 5 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | 3 | 2 | 5 |
| Mania | D000087122 | — | F30 | 2 | 2 | — | 1 | — | 4 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 2 | 2 | — | 1 | — | 4 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 2 | 1 | — | 3 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | 1 | 1 | 3 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | 2 | — | 3 |
| Neoplasms | D009369 | — | C80 | — | — | — | 3 | — | 3 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cholestasis | D002779 | — | K83.1 | — | — | 1 | — | 1 | 2 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
| Binge-eating disorder | D056912 | — | F50.2 | — | 1 | 1 | — | — | 1 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | 1 | — | — | 1 |
| Peripartum cardiomyopathy | D000099088 | — | O90.3 | — | 1 | 1 | — | — | 1 |
| Prehypertension | D058246 | — | — | — | — | 1 | — | — | 1 |
| Xerostomia | D014987 | — | K11.7 | — | — | 1 | — | — | 1 |
| Post-acute covid-19 syndrome | D000094024 | — | — | — | 1 | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammation | D007249 | MP_0001845 | — | — | 2 | — | — | 2 | 4 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | 2 | 3 |
| Fragile x syndrome | D005600 | — | Q99.2 | 2 | 1 | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | 2 | 3 |
| Periodontitis | D010518 | EFO_0000649 | K05.3 | 1 | 1 | — | — | 2 | 3 |
| Alcohol-related disorders | D019973 | — | F10 | 1 | 1 | — | — | — | 2 |
| Healthy volunteers/patients | — | — | — | — | 1 | — | — | 1 | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 2 |
| Homocystinuria | D006712 | — | E72.11 | 2 | 2 | — | — | — | 2 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 2 | — | — | — | 2 |
Show 36 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Driving under the influence | D000066448 | — | — | 1 | — | — | — | 1 | 2 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | 1 | — | — | — | 1 | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | — | — | — | 1 |
| Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | 1 | — | — | — | — | 1 |
| Sclerosis | D012598 | — | — | 1 | — | — | — | — | 1 |
| Tinnitus | D014012 | — | H93.1 | 1 | — | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 6 | 6 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 4 | 4 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | — | — | 3 | 3 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | — | 3 | 3 |
| Weight loss | D015431 | — | — | — | — | — | — | 2 | 2 |
| Self concept | D012649 | — | — | — | — | — | — | 2 | 2 |
| Blood pressure | D001794 | EFO_0004325 | — | — | — | — | — | 2 | 2 |
| Muscular atrophy | D009133 | — | — | — | — | — | — | 2 | 2 |
| Protein deficiency | D011488 | — | — | — | — | — | — | 2 | 2 |
| Sensitivity training groups | D012681 | — | — | — | — | — | — | 2 | 2 |
Show 89 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Taurine |
| INN | taurine |
| Description | Taurine is an amino sulfonic acid that is the 2-amino derivative of ethanesulfonic acid. It is a naturally occurring amino acid derived from methionine and cysteine metabolism. An abundant component of fish- and meat-based foods, it has been used as an oral supplement in the treatment of disorders such as cystic fibrosis and hypertension. It has a role as a human metabolite, an antioxidant, a mouse metabolite, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite, a glycine receptor agonist, a nutrient and a radical scavenger. It is a conjugate acid of a 2-aminoethanesulfonate. It is a tautomer of a taurine zwitterion. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NCCS(=O)(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 107-35-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL239243 |
| ChEBI ID | 15891 |
| PubChem CID | 1123 |
| DrugBank | DB01956 |
| UNII ID | 1EQV5MLY3D (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 48,966 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
164 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use